Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHUGANJIEYUEJIAONANG + mosapride for functional dyspepsia
ChiCTR-IPR-17010704Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2016
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional dyspepsia (FD) comparing mosapride + SHUGANJIEYUEJIAONANG with mosapride + placebo (2 arms). Primary endpoint: Symptom curative effect at 6 weeks. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on ChiCTR-IPR-17010704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010704.